{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:09:37Z","timestamp":1783976977889,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.survophthal.2026.07.001","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:59:34Z","timestamp":1783627174000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-approval outcomes of voretigene neparvovec (Luxturna\u00ae) retinal gene therapy: A systematic review and meta-analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7235-3900","authenticated-orcid":false,"given":"Jessica X.L.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia C.","family":"Rowson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layal","family":"Naji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Simunovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2026.07.001_bib1","first-page":"23","article-title":"Congenital stationary night blindness in the dog: common mutation in the RPE65 gene indicates founder effect","volume":"4","author":"Aguirre","year":"1998","journal-title":"Mol Vis"},{"issue":"4","key":"10.1016\/j.survophthal.2026.07.001_bib2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cell.2015.03.023","article-title":"Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis","volume":"161","author":"A\u00eft-Ali","year":"2015","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.survophthal.2026.07.001_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22137207","article-title":"Inherited retinal diseases due to RPE65 variants: from genetic diagnostic management to therapy","volume":"22","author":"Aoun","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"26","key":"10.1016\/j.survophthal.2026.07.001_bib4","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/hmg\/10.26.3075","article-title":"Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model","volume":"10","author":"Auricchio","year":"2001","journal-title":"Hum Mol Genet"},{"issue":"20","key":"10.1016\/j.survophthal.2026.07.001_bib5","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber's congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.survophthal.2026.07.001_bib6","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber's congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2026.07.001_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/ijms232113467","article-title":"Inherited retinal diseases","volume":"23","author":"Ben-Yosef","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.survophthal.2026.07.001_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.preteyeres.2010.03.004","article-title":"The molecular basis of human retinal and vitreoretinal diseases","volume":"29","author":"Berger","year":"2010","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"10.1016\/j.survophthal.2026.07.001_bib9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.oret.2023.08.017","article-title":"Classification and growth rate of chorioretinal atrophy after voretigene neparvovec-rzyl for RPE65-mediated retinal degeneration","volume":"8","author":"Bommakanti","year":"2024","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.survophthal.2026.07.001_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ajo.2018.09.024","article-title":"The natural history of inherited retinal dystrophy due to biallelic mutations in the RPE65 gene","volume":"199","author":"Chung","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2026.07.001_bib11","doi-asserted-by":"crossref","first-page":"E517","DOI":"10.1073\/pnas.1218933110","article-title":"Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement","volume":"110","author":"Cideciyan","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.survophthal.2026.07.001_bib12","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00417-021-05508-2","article-title":"Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis","volume":"260","author":"Deng","year":"2022","journal-title":"Graefe\u2019S Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2026.07.001_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e25154","article-title":"Could internal limiting membrane peeling before Voretigen neparvovec-ryzl subretinal injection prevent focal chorioretinal atrophy?","volume":"10","author":"Dormegny","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.survophthal.2026.07.001_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/biom14010122","article-title":"Real-world safety and effectiveness of voretigene neparvovec: results up to 2 years from the prospective, registry-based PERCEIVE study","volume":"14","author":"Fischer","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.survophthal.2026.07.001_bib15","unstructured":"FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss [press release]. 2017. ."},{"issue":"1","key":"10.1016\/j.survophthal.2026.07.001_bib16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","article-title":"Perifoveal chorioretinal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-mediated Leber congenital amaurosis","volume":"6","author":"Gange","year":"2022","journal-title":"Ophthalmol Retin"},{"issue":"1","key":"10.1016\/j.survophthal.2026.07.001_bib17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13023-021-01807-3","article-title":"Frequency and phenotypic characteristics of RPE65 mutations in the Chinese population","volume":"16","author":"Gao","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.survophthal.2026.07.001_bib18","first-page":"1","article-title":"Gene therapy with voretigene neparvovec improves vision and partially restores electrophysiological function in pre-school children with Leber congenital amaurosis","volume":"11","author":"Gerhardt","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.survophthal.2026.07.001_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1101\/cshperspect.a041277","article-title":"Comparison of worldwide disease prevalence and genetic prevalence of inherited retinal diseases and variant interpretation considerations","volume":"14","author":"Hanany","year":"2024","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10","key":"10.1016\/j.survophthal.2026.07.001_bib20","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.survophthal.2026.07.001_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"Higgins","year":"2024","journal-title":"Environ Int"},{"key":"10.1016\/j.survophthal.2026.07.001_bib22","series-title":"AAV-associated toxicity caused by transgene expression in the retinal pigment epithelium [dissertation]","author":"Hong","year":"2023"},{"issue":"2","key":"10.1016\/j.survophthal.2026.07.001_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1167\/tvst.7.2.19","article-title":"Volumetric measurement of subretinal blebs using microscope-integrated optical coherence tomography","volume":"7","author":"Hsu","year":"2018","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.survophthal.2026.07.001_bib24","series-title":"Version 29020 Armonk","article-title":"Statistics for Windows","author":"Corp","year":"2023"},{"issue":"6","key":"10.1016\/j.survophthal.2026.07.001_bib25","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ymthe.2006.03.005","article-title":"Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection","volume":"13","author":"Jacobson","year":"2006","journal-title":"Mol Ther"},{"issue":"20","key":"10.1016\/j.survophthal.2026.07.001_bib26","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1412965","article-title":"Improvement and decline in vision with gene therapy in childhood blindness","volume":"372","author":"Jacobson","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.survophthal.2026.07.001_bib27","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1159\/000530086","article-title":"Long-term follow-up of a family with retinal dystrophy caused by RPE65 mutation","volume":"14","author":"J\u00e1nossy","year":"2023","journal-title":"Case Rep Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.07.001_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10633-023-09962-7","article-title":"ISCEV and IPS guideline for the full-field stimulus test (FST)","volume":"148","author":"Jolly","year":"2024","journal-title":"Doc Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2026.07.001_bib29","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ophtha.2022.06.018","article-title":"Inflammation after voretigene neparvovec administration in patients with RPE65-related retinal dystrophy","volume":"129","author":"Kessel","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2026.07.001_bib30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/biom13101484","article-title":"Outcomes and adverse effects of voretigene neparvovec treatment for biallelic RPE65-mediated inherited retinal dystrophies in a cohort of patients from a single center","volume":"13","author":"Kiraly","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.survophthal.2026.07.001_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2021.108761","article-title":"RPE65-related retinal dystrophy: mutational and phenotypic spectrum in 45 affected patients","volume":"212","author":"Lopez-Rodriguez","year":"2021","journal-title":"Exp Eye Res"},{"issue":"2","key":"10.1016\/j.survophthal.2026.07.001_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ophtha.2023.09.006","article-title":"Single center experience with voretigene neparvovec gene augmentation therapy in RPE65 mutation-associated inherited retinal degeneration in a clinical setting","volume":"131","author":"Lorenz","year":"2024","journal-title":"Ophthalmology"},{"issue":"21","key":"10.1016\/j.survophthal.2026.07.001_bib33","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber's congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N Engl J Med"},{"issue":"9701","key":"10.1016\/j.survophthal.2026.07.001_bib34","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","article-title":"Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial","volume":"374","author":"Maguire","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.survophthal.2026.07.001_bib35","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","article-title":"Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease: phase 3 results at 3 and 4 years","volume":"128","author":"Maguire","year":"2021","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.survophthal.2026.07.001_bib36","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation\u2013associated inherited retinal dystrophy: results of phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2026.07.001_bib37","unstructured":"Medical Services Advisory Committee. Application no. 1623 \u2013 luxturnaTM (voretigene neparvovec) for the treatment of biallelic RPE-65-mediated inherited retinal dystrophies. Australian Government; 2020. ."},{"issue":"2","key":"10.1016\/j.survophthal.2026.07.001_bib38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.exer.2007.05.003","article-title":"A novel cone visual cycle in the cone-dominated retina","volume":"85","author":"Muniz","year":"2007","journal-title":"Exp Eye Res"},{"issue":"8","key":"10.1016\/j.survophthal.2026.07.001_bib39","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/aos.13141","article-title":"A review of the mechanisms of cone degeneration in retinitis pigmentosa","volume":"94","author":"Narayan","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2026.07.001_bib40","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/IAE.0000000000001029","article-title":"Novel technique for subretinal injection using local removal of the internal limiting membrane","volume":"36","author":"Okanouchi","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2026.07.001_bib41","article-title":"statement: an updated guideline for reporting systematic reviews","volume":"2021","author":"Page","year":"2020","journal-title":"Br Med J"},{"key":"10.1016\/j.survophthal.2026.07.001_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/IAE.0000000000002681","article-title":"Longitudinal study of RPE65-associated inherited retinal degenerations","volume":"40","author":"Pierrache","year":"2020","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.survophthal.2026.07.001_bib43","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.ophtha.2020.04.008","article-title":"Genetic basis of inherited retinal disease in a molecularly characterized cohort of more than 3000 families from the united kingdom","volume":"127","author":"Pontikos","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2026.07.001_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2025.101354","article-title":"Gene therapy-associated uveitis (GTAU): understanding and mitigating the adverse immune response in retinal gene therapy","volume":"106","author":"Purdy","year":"2025","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"10.1016\/j.survophthal.2026.07.001_bib45","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/3813","article-title":"RPE65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle","volume":"20","author":"Redmond","year":"1998","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.survophthal.2026.07.001_bib46","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/bjophthalmol-2021-321023","article-title":"Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec","volume":"107","author":"Reichel","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.07.001_bib47","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1167\/iovs.12-11341","article-title":"Intervisit variability of visual parameters in Leber congenital amaurosis caused by RPE65 mutations","volume":"54","author":"Roman","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.survophthal.2026.07.001_bib48","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.ophtha.2005.01.040","article-title":"The correlation between height of macular detachment and visual outcome in macula-off retinal detachments of < or = 7 days' duration","volume":"112","author":"Ross","year":"2005","journal-title":"Ophthalmology"},{"issue":"10097","key":"10.1016\/j.survophthal.2026.07.001_bib49","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.survophthal.2026.07.001_bib50","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/sctm.18-0210","article-title":"Optimizing donor cellular dissociation and subretinal injection parameters for stem cell-based treatments","volume":"8","author":"Scruggs","year":"2019","journal-title":"Stem Cells Transl Med"},{"issue":"10-11","key":"10.1016\/j.survophthal.2026.07.001_bib51","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41434-021-00294-2","article-title":"Injection pressure levels for creating blebs during subretinal gene therapy","volume":"29","author":"Scruggs","year":"2022","journal-title":"Gene Ther"},{"key":"10.1016\/j.survophthal.2026.07.001_bib52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.xops.2024.100516","article-title":"Dose-dependent progression of chorioretinal atrophy at the injection site after subretinal injection of rAAV2\/8 in nonhuman primates","volume":"4","author":"Seitz","year":"2024","journal-title":"Ophthalmol Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2026.07.001_bib53","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.oret.2021.11.005","article-title":"Visual acuity, retinal morphology, and patients' perceptions after voretigene neparovec-rzyl therapy for RPE65-associated retinal disease","volume":"6","author":"Sengillo","year":"2022","journal-title":"Ophthalmol Retin"},{"issue":"1","key":"10.1016\/j.survophthal.2026.07.001_bib54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41433-023-02636-3","article-title":"Full-field stimulus threshold testing: a scoping review of current practice","volume":"38","author":"Shi","year":"2024","journal-title":"Eye"},{"issue":"4","key":"10.1016\/j.survophthal.2026.07.001_bib55","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.survophthal.2022.01.008","article-title":"Vision at the limits: absolute threshold, visual function, and outcomes in clinical trials","volume":"67","author":"Simunovic","year":"2022","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.07.001_bib56","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/opo.12743","article-title":"Threshold versus intensity functions in two-colour automated perimetry","volume":"41","author":"Simunovic","year":"2021","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.survophthal.2026.07.001_bib57","series-title":"Comprehensive pharmacology","first-page":"662","article-title":"3.30 - Gene therapy, diet and drug approaches to treating inherited retinal disease","author":"Simunovic","year":"2022"},{"issue":"3","key":"10.1016\/j.survophthal.2026.07.001_bib58","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/opo.13280","article-title":"Mechanisms of cone sensitivity loss in retinitis pigmentosa","volume":"44","author":"Simunovic","year":"2024","journal-title":"Ophthalmic Physiol Opt"},{"issue":"2","key":"10.1016\/j.survophthal.2026.07.001_bib59","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/IAE.0000000000004296","article-title":"The fight inherited retinal blindness! project: a new treatment outcome and natural history registry for inherited retinal disease","volume":"45","author":"Simunovic","year":"2025","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2026.07.001_bib60","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ajo.2025.02.018","article-title":"The 1-step versus 2-step subretinal injection trial (1,2-SIT)-a randomized controlled trial to compare drug reflux following subretinal injection","volume":"274","author":"Simunovic","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2026.07.001_bib61","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaophthalmol.2016.5630","article-title":"Structural and functional recovery following limited iatrogenic macular detachment for retinal gene therapy","volume":"135","author":"Simunovic","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.07.001_bib62","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/tvst.13.2.13","article-title":"Chorioretinal atrophy growth after voretigene neparvovec retinotopically is connected to retinal functional rescue","volume":"13","author":"Stingl","year":"2024","journal-title":"Transl Vis Sci Technol"},{"issue":"7","key":"10.1016\/j.survophthal.2026.07.001_bib63","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ophtha.2023.02.015","article-title":"Full-field scotopic threshold improvement after voretigene neparvovec-rzyl treatment correlates with chorioretinal atrophy","volume":"130","author":"Stingl","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2026.07.001_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/s41433-024-03065-6","article-title":"Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice","author":"Testa","year":"2024","journal-title":"Eye"},{"issue":"10","key":"10.1016\/j.survophthal.2026.07.001_bib65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/tvst.10.10.11","article-title":"Voretigene neparvovec gene therapy in clinical practice: treatment of the first two italian pediatric patients","volume":"10","author":"Testa","year":"2021","journal-title":"Transl Vis Sci Technol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.07.001_bib66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/iovs.63.2.13","article-title":"RPE65-associated retinopathies in the Italian population: a longitudinal natural history study","volume":"63","author":"Testa","year":"2022","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"13","key":"10.1016\/j.survophthal.2026.07.001_bib67","first-page":"4293","article-title":"Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration.","volume":"41","author":"Thompson","year":"2000","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.survophthal.2026.07.001_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/biom11050760","article-title":"A systematic review and meta-analyses of interventional clinical trial studies for gene therapies for the inherited retinal degenerations (IRDs)","volume":"11","author":"Tuohy","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.survophthal.2026.07.001_bib69","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13023-020-1304-1","article-title":"The effect of human gene therapy for RPE65-associated Leber's congenital amaurosis on visual function: a systematic review and meta-analysis","volume":"15","author":"Wang","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"10.1016\/j.survophthal.2026.07.001_bib70","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1073\/pnas.1821000116","article-title":"AAV cis-regulatory sequences are correlated with ocular toxicity","volume":"116","author":"Xiong","year":"2019","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726000913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726000913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:24:21Z","timestamp":1783974261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625726000913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":70,"alternative-id":["S0039625726000913"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.07.001","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-approval outcomes of voretigene neparvovec (Luxturna\u00ae) retinal gene therapy: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}